What they were paid
GoodRx Director Compensation Table · all 4 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $5,440 | $510,214 | $0 | $0 | $515,654 |
| FY2024 | $5,440 | $510,214 | $0 | $0 | $515,654 |
| FY2023 | $0 | $0 | $0 | $0 | $0 |
| FY2022 | $0 | $0 | $0 | $0 | $0 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GoodRx Holdings, Inc. DEF 14A filed April 29, 2026, accession 0001809519-26-000091, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025GoodRx pays directors a $30,000 cash retainer and $230,000 in RSUs.
Committees
FY2025 · as the proxy prints themExecutive
The rest of the GoodRx board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Agnes Rey-Giraud | Independent Director | $315,159 |
| Christopher Adams | Independent Director | $0 |
| Dipanjan Deb | Independent Director | $0 |
| Gregory Mondre | Independent Director | $0 |
| Ian T. Clark | Independent Director | $647,435 |
| Kelly J. Kennedy | Independent Director | $299,780 |
| Ronald E. Bruehlman | Independent Director | $425,756 |
| Scott Wagner | Director | $0 |
| Trevor Bezdek | Chair of the Board | $0 |
| Wendy Barnes | Director | $0 |
The full GoodRx compensation record
free company briefThis page is one director within GoodRx's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat